{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T08:00:54Z","timestamp":1795075254497,"version":"4.10.2"},"reference-count":46,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"unspecified","delay-in-days":82,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,6,10]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Psoriatic arthritis (PsA) is a chronic inflammatory condition associated with psoriasis and characterised by heterogeneous clinical manifestations, including peripheral and axial arthritis, enthesitis and dactylitis. A subset of patients exhibits a \u2018difficult-to-treat\u2019 (D2T) phenotype, necessitating complex therapeutic strategies. Metabolic syndrome (MetS) is highly prevalent in PsA patients and has been implicated in increased disease activity.<\/jats:p>\n                  <jats:p>This study aimed to evaluate the impact of MetS on the development of D2T phenotype in PsA and its potential implications for disease management.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A cross-sectional study was conducted on PsA patients recruited from the Rheumatology Clinic at Fondazione Policlinico Campus Bio-Medico of Rome. Patients fulfilling the Classification Criteria for Psoriatic Arthritis criteria were assessed for disease activity and the presence of MetS according to National Cholesterol Education Programme Adult Treatment Panel III criteria. D2T PsA was defined based on the Rheumatoid Arthritis European Alliance of Associations for Rheumatolog criteria revised for PsA by Perrotta <jats:italic>et al.<\/jats:italic> Statistical analyses, including logistic regression and path analysis, were performed to explore associations between MetS and D2T PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 182 PsA patients, 42.94% met MetS criteria. The D2T subset (n=66) demonstrated a significantly higher prevalence of MetS (81.82% vs 29.37%, p&lt;0.0001). Logistic regression revealed a strong association between MetS and D2T PsA (OR 7.56, 95%\u2009CI 2.53 to 22.56, p&lt;0.0001), and path analysis confirmed MetS as an independent predictor of D2T phenotype.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>MetS is strongly associated with a D2T phenotype in PsA, suggesting that metabolic comorbidities contribute to disease severity and treatment resistance. Addressing metabolic dysfunction may be crucial in optimising therapeutic outcomes in PsA management.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-005717","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T20:45:18Z","timestamp":1750625118000},"page":"e005717","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Patients with psoriatic arthritis and comorbid metabolic syndrome show a difficult-to-treat phenotype: another mosaic tile in the definition of a still undefined subset of patients"],"prefix":"10.1136","volume":"11","author":[{"given":"Damiano","family":"Currado","sequence":"first","affiliation":[{"name":"Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine, Rome, Italy"},{"name":"Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Universitario Campus Bio-Medico, via Alvaro del Portillo 200, 00128, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Trunfio","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Saracino","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyubomyra","family":"Kun","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Marino","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Corberi","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Orlando","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Lamberti","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Frasc\u00e0","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gatti","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2808-1581","authenticated-orcid":false,"given":"Onorina","family":"Berardicurti","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine, Rome, Italy"},{"name":"Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Universitario Campus Bio-Medico, via Alvaro del Portillo 200, 00128, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vomero","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine, Rome, Italy"},{"name":"Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Universitario Campus Bio-Medico, via Alvaro del Portillo 200, 00128, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Liakouli","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania \"Luigi Vanvitelli\", University of Campania \"Luigi Vanvitelli\", Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine, Rome, Italy"},{"name":"Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Universitario Campus Bio-Medico, via Alvaro del Portillo 200, 00128, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Navarini","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine, Rome, Italy"},{"name":"Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Universitario Campus Bio-Medico, via Alvaro del Portillo 200, 00128, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,22]]},"reference":[{"key":"2025090313460917000_11.2.e005717.1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06605-9"},{"key":"2025090313460917000_11.2.e005717.2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s40744-023-00574-w","article-title":"Difficult to Treat and Refractory to Treatment in Psoriatic Arthritis","volume":"10","author":"Lubrano","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025090313460917000_11.2.e005717.3","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s10067-020-05027-1","article-title":"Retention rates and identification of factors associated with anti-TNF\u03b1, anti-IL17, and anti-IL12\/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting","volume":"39","author":"Navarini","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2025090313460917000_11.2.e005717.4","first-page":"487","article-title":"Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future","volume":"12","author":"Navarini","year":"2020","journal-title":"J Exp Pharmacol"},{"key":"2025090313460917000_11.2.e005717.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220310"},{"key":"2025090313460917000_11.2.e005717.6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clinthera.2023.01.006","article-title":"Comorbidities in Psoriatic Arthritis: A Narrative Review","volume":"45","author":"Panagiotopoulos","year":"2023","journal-title":"Clin Ther"},{"key":"2025090313460917000_11.2.e005717.7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205506","article-title":"Performances of five risk algorithms in predicting cardiovascular events in patients with Psoriatic Arthritis: An Italian bicentric study","volume":"13","author":"Navarini","year":"2018","journal-title":"PLoS One"},{"key":"2025090313460917000_11.2.e005717.8","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/rheumatology\/kez677","article-title":"A machine-learning approach to cardiovascular risk prediction in psoriatic arthritis","volume":"59","author":"Navarini","year":"2020","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025090313460917000_11.2.e005717.9","doi-asserted-by":"crossref","first-page":"152389","DOI":"10.1016\/j.semarthrit.2024.152389","article-title":"The management of cardiovascular risk in psoriatic disease: A bridge over troubled water","volume":"65","author":"Alunno","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313460917000_11.2.e005717.10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40744-025-00758-6","article-title":"The Relationship Between Metabolic Syndrome and Pain Catastrophizing in Psoriatic Arthritis","volume":"12","author":"Currado","year":"2025","journal-title":"Rheumatol Ther"},{"key":"2025090313460917000_11.2.e005717.11","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2024.1467555","article-title":"Euthymic despite pain: the role of cognitive reappraisal and experiential avoidance in autoimmune inflammatory rheumatic diseases-a cross-sectional study","volume":"15","author":"De Vincenzo","year":"2024","journal-title":"Front Psychol"},{"key":"2025090313460917000_11.2.e005717.12","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033362","article-title":"Cardiometabolic multimorbidity may identify a more severe subset of rheumatoid arthritis, results from a \u201creal-life\u201d study","volume":"102","author":"Ruscitti","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"2025090313460917000_11.2.e005717.13","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-024-03392-9","article-title":"Diminished expression of the ubiquitin-proteasome system in early treatment-na\u00efve patients with rheumatoid arthritis and concomitant type 2 diabetes may be linked to IL-1 pathway hyper-activity; results from PEAC cohort","volume":"26","author":"Ruscitti","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"2025090313460917000_11.2.e005717.14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.169404"},{"key":"2025090313460917000_11.2.e005717.15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40744-022-00502-4","article-title":"Discrepancy in Metabolic Syndrome between Psoriatic Arthritis and Rheumatoid Arthritis: a Direct Comparison of Two Cohorts in One Center","volume":"10","author":"Li","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025090313460917000_11.2.e005717.16","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1097\/RHU.0000000000001738","article-title":"Prevalence of Metabolic Syndrome in Psoriatic Arthritis: Systematic Literature Review and Results From the CARMA Cohort","volume":"28","author":"Urruticoechea-Arana","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"2025090313460917000_11.2.e005717.17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/1744666X.2020.1740593","article-title":"Metabolic Syndrome and psoriatic arthritis: considerations for the clinician","volume":"16","author":"Caso","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"2025090313460917000_11.2.e005717.18","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8595-z"},{"key":"2025090313460917000_11.2.e005717.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04458-7"},{"key":"2025090313460917000_11.2.e005717.20","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/RHU.0000000000000721","article-title":"Increased Prevalence of Metabolic Syndrome and Adipocytokine Levels in a Psoriatic Arthritis Cohort","volume":"24","author":"Feld","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"2025090313460917000_11.2.e005717.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217344"},{"key":"2025090313460917000_11.2.e005717.22","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00461-w"},{"key":"2025090313460917000_11.2.e005717.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-0101"},{"key":"2025090313460917000_11.2.e005717.24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10067-017-3975-0","article-title":"Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study","volume":"37","author":"Caso","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025090313460917000_11.2.e005717.25","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1093\/rheumatology\/keae263","article-title":"Identification and characteristics of patients with potential difficult-to-treat psoriatic arthritis: exploratory analyses of the Greek PsA registry","volume":"63","author":"Vassilakis","year":"2024","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025090313460917000_11.2.e005717.26","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s10067-019-04619-w","article-title":"Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset \u201csine psoriasis\u201d","volume":"38","author":"Caso","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025090313460917000_11.2.e005717.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04775-2"},{"key":"2025090313460917000_11.2.e005717.28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.reuma.2021.05.005","article-title":"Psoriatic arthritis: interaction between cardiometabolic diseases and inflammatory burden of the disease","volume":"18","author":"Lorenzo Mart\u00edn","year":"2022","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"2025090313460917000_11.2.e005717.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2025090313460917000_11.2.e005717.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.08.012"},{"key":"2025090313460917000_11.2.e005717.31","doi-asserted-by":"crossref","DOI":"10.1186\/1751-0473-3-17","article-title":"Purposeful selection of variables in logistic regression","volume":"3","author":"Bursac","year":"2008","journal-title":"Source Code Biol Med"},{"key":"2025090313460917000_11.2.e005717.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152275"},{"key":"2025090313460917000_11.2.e005717.33","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003809","article-title":"Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project","volume":"10","author":"Singla","year":"2024","journal-title":"RMD Open"},{"key":"2025090313460917000_11.2.e005717.34","first-page":"41","article-title":"Potential difficult-to-treat psoriatic arthritis real-world prevalence and contributing factors","volume":"43","author":"Alp","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313460917000_11.2.e005717.35","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X241271886","article-title":"Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy","volume":"16","author":"Williams","year":"2024","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025090313460917000_11.2.e005717.36","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14147"},{"key":"2025090313460917000_11.2.e005717.37","doi-asserted-by":"crossref","first-page":"103357","DOI":"10.1016\/j.autrev.2023.103357","article-title":"Effect of body mass index on treatment response of biologic\/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review","volume":"22","author":"Gialouri","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2025090313460917000_11.2.e005717.38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/OARRR.S347797","article-title":"Metabolic Syndrome and Its Components in Psoriatic Arthritis","volume":"14","author":"Aljohani","year":"2022","journal-title":"Open Access Rheumatol"},{"key":"2025090313460917000_11.2.e005717.39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0302391","article-title":"Association between the severity of hard-to-treat psoriasis and the prevalence of metabolic syndrome: A hospital-based cross-sectional study in Jakarta, Indonesia","volume":"19","author":"Evyana","year":"2024","journal-title":"PLoS One"},{"key":"2025090313460917000_11.2.e005717.40","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0380-5"},{"key":"2025090313460917000_11.2.e005717.41","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.121"},{"key":"2025090313460917000_11.2.e005717.42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/art.43034","article-title":"Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis","volume":"77","author":"Baker","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2025090313460917000_11.2.e005717.43","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-1210"},{"key":"2025090313460917000_11.2.e005717.44","first-page":"1856","article-title":"The negative impact of pain catastrophising on disease activity: analyses of data derived from patient-reported outcomes in psoriatic arthritis and axial spondyloarthritis","volume":"41","author":"Currado","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313460917000_11.2.e005717.45","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-024-03396-5","article-title":"Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study","volume":"26","author":"Currado","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"2025090313460917000_11.2.e005717.46","first-page":"1150","article-title":"Association between Patient Acceptable Symptom State and disease activity in psoriatic arthritis is disrupted by confounders, including comorbid fibromyalgia","volume":"42","author":"Navarini","year":"2024","journal-title":"Clin Exp Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-005717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:46:23Z","timestamp":1756932383000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-005717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,22]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/rmdopen-2025-005717"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-005717","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}